Symic raises $25M in series A-2 round
Symic Biomedical Inc. (San Francisco, Calif.) raised $25 million in a series A-2 round led by existing investor Lilly Ventures. New investors Alexandria Real Estate and Purdue Research Foundation also participated, as did existing investors Den Danske Forskningsfond, Mitsui Global Investment, Ally Bridge Group, InCube Ventures, Purdue Foundry Investment Fund, Mission Bay Capital and QB3 Partners.
Symic develops therapeutics that mimic proteoglycans to treat inflammatory conditions. The company has two clinical candidates. In early 2016 it expects data from the Phase I/II SHIELD study of SB-030 to reduce neointimal hyperplasia following percutaneous transluminal angioplasty (PTA), and it expects to start a Phase I/II trial of SB-061 to treat osteoarthritis in 2Q16. ...